Liquidia Corporation Stock Price, News & Analysis

Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company focused on rare cardiopulmonary disease treatments, will release its Q2 2025 financial results on Tuesday, August 12, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss the results and provide a corporate update. Investors can access the webcast through Liquidia's website, where it will remain archived for one year.

Liquidia Corporation (NASDAQ: LQDA) has received $50 million from Healthcare Royalty (HCRx) following the first commercial sale of YUTREPIA™ and a favorable court decision denying United Therapeutics' request for an injunction. This funding brings the total received to $175 million out of a potential $200 million under their agreement.

The company plans to use the proceeds to accelerate YUTREPIA's launch, advance its clinical pipeline, and expand manufacturing operations. Management believes Liquidia can achieve profitability without additional capital. The funding terms include a fixed payment schedule through 2033, with aggregate payments capped at 175% of funded amounts and a minimum 13% internal rate of return requirement.

Liquidia Corporation announced its first commercial shipment of YUTREPIA (treprostinil) inhalation powder, following FDA approval on May 23, 2025. The drug is now available for prescription through specialty pharmacies for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company achieved rapid market deployment within five business days of approval, including sales force mobilization and compendia listing. Notably, United Therapeutics' attempt to block YUTREPIA's launch through a preliminary injunction and temporary restraining order was denied by the U.S. District Court, which concluded UTHR was unlikely to succeed in their patent infringement claims regarding U.S. Patent No. 11,357,782.

Liquidia Corporation (NASDAQ: LQDA) has announced that its leadership team will participate in the 2025 Jefferies Global Healthcare Conference on June 4, 2025, at 11:05 a.m. ET in New York City. The presentation will feature CEO Dr. Roger Jeffs, CFO/COO Michael Kaseta, and CBO Jason Adair in a fireside chat format to provide business updates. Investors can access the webcast through Liquidia's website, where a recording will remain available for at least 30 days after the event.

The FDA has approved Liquidia's (NASDAQ: LQDA) YUTREPIA™, a novel inhalation powder form of treprostinil for treating adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). YUTREPIA is the first prostacyclin dry-powder formulation using Liquidia's proprietary PRINT™ technology, designed for enhanced deep-lung delivery through a low-effort device. The approval is based on the successful Phase 3 INSPIRE trial, which demonstrated safety and tolerability in both treprostinil-naïve patients and those transitioning from nebulized treprostinil. However, United Therapeutics (UTHR) has filed a patent infringement complaint and seeks to block YUTREPIA's commercial launch through a temporary restraining order and preliminary injunction, with the motion currently pending.

Liquidia Corporation (NASDAQ: LQDA) faces new litigation from United Therapeutics (UTHR) over alleged patent infringement. The lawsuit, filed on May 9, 2025, in North Carolina's U.S. District Court, concerns UTHR's '782 patent and seeks to prevent Liquidia from commercializing YUTREPIA™, their inhaled treprostinil treatment for PAH and PH-ILD.

The disputed '782 patent is from the same family as UTHR's previously invalidated '793 patent. Notably, the '793 patent was declared invalid by the Patent Trial and Appeal Board (PTAB), a decision upheld through multiple appeals including the Supreme Court. The litigation does not affect FDA's ability to approve YUTREPIA, which has a PDUFA date of May 24, 2025.

Liquidia Corporation (NASDAQ: LQDA) reported Q1 2025 financial results and provided key updates. The company awaits FDA action on YUTREPIA™ with a PDUFA date of May 24, 2025. Notable developments include: the District Court's dismissal of United Therapeutics' cross-claim challenging the PH-ILD amendment, full enrollment of Cohort A in the ASCENT study for PH-ILD patients, and access to up to $100M in additional financing from HealthCare Royalty. Q1 financials show cash position of $169.8M, revenue of $3.1M, and net loss of $38.4M ($0.45 per share). R&D expenses decreased 31% to $7.0M, while G&A expenses increased 48% to $30.1M, primarily due to preparation for YUTREPIA's potential commercialization.

Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company focused on rare cardiopulmonary disease treatments, will participate in the BofA Securities 2025 Health Care Conference. The company's CFO/COO Michael Kaseta and CMO Rajeev Saggar will deliver a business update in a fireside chat on May 13, 2025, at 1:40 PM PT / 4:40 PM ET in Las Vegas. Investors can access the webcast through Liquidia's website, where a recording will remain available for at least 30 days after the event.

The U.S. District Court for the District of Columbia has dismissed United Therapeutics' (UTHR) cross-claim challenging Liquidia's (LQDA) amended New Drug Application for YUTREPIA™. The court ruled that UTHR's claim was unripe and lacked standing. The amended NDA seeks to add the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) to YUTREPIA's label.

The FDA has already granted tentative approval for YUTREPIA and set a PDUFA goal date of May 24, 2025. Final approval can be granted after the blocking regulatory exclusivity expires on May 23, 2025. While UTHR maintains the right to appeal, Liquidia's CEO expressed confidence in the FDA's decision to accept and tentatively approve the amended NDA.